Current Therapies for Chronic Hepatitis C

نویسندگان

چکیده

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Current therapies for chronic hepatitis C.

Hepatitis C virus affects more than 180 million people worldwide and as many as 4 million people in the United States. Given that most patients are asymptomatic until late in the disease progression, diagnostic screening and evaluation should be performed in patients who display high-risk behaviors associated with acquisition of hepatitis C. Chronic hepatitis C is associated with cirrhosis, hep...

متن کامل

Current therapies for chronic hepatitis B.

Chronic hepatitis B is a major public health problem and there are an estimated 400 million people worldwide infected with the Hepatitis B virus (HBV). It is one of the most common causes of hepatic cirrhosis and hepatocarcinoma. The prevalence of chronic hepatitis B varies in different geographic locations. In the Western countries, hepatitis B is the third most common cause of chronic liver d...

متن کامل

Current and Future Therapies for Hepatitis C Virus Infection

From the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD. Address reprint requests to Dr. Liang at the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg. 10-9B16, 10 Center Dr., Bethesda, MD 20892-1800, or at [email protected].

متن کامل

Current and future therapies for hepatitis C virus infection.

From the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD. Address reprint requests to Dr. Liang at the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg. 10-9B16, 10 Center Dr., Bethesda, MD 20892-1800, or at [email protected].

متن کامل

Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C.

Until HCV NS3/4A protease inhibitors become available at the end of 2011, the combination pegylated-interferon (PEG-IFN)-alfa and ribavirin (RBV) will remain the standard treatment for chronic hepatitis C patients. In some hepatitis C virus-infected patients, PEG-IFN plus RBV treatment against HCV should continue to be used because of side effects of new drugs such as anemia. Our Japanese exper...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Pharmacotherapy

سال: 2011

ISSN: 0277-0008

DOI: 10.1592/phco.31.1.92